Intensity Therapeutics (INTS) Other financing activities (2023 - 2025)
Intensity Therapeutics' (INTS) quarterly Other financing activities came in at -$4.6 million in Q4 2025, down 1531.78% YoY from $321000.0 in Q4 2024, and down 198.8% on a QoQ basis from $4.7 million in Q2 2025.
Intensity Therapeutics (INTS) Other financing activities (2023 - 2025) Analysis & Trends
Intensity Therapeutics (INTS) has 3 years of Other financing activities data on file, last reported at -$4.6 million in Q4 2025.
- Quarterly Other financing activities fell 1531.78% year-over-year to -$4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $56000.0 (down 82.55% YoY) and the FY2025 annual result came in at $56000.0, down 82.55% from the prior year.
- Other financing activities retreated to -$4.6 million in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $22.4 million in Q4 2023 to a low of -$4.6 million in Q4 2025.
- A 3-year average of $3.3 million and a median of $50000.0 in 2023 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 58250.0% in 2025, down 1531.78% in 2025.
- Tracing INTS's Other financing activities over 3 years: stood at $22.4 million in 2023, then sank by 98.57% to $321000.0 in 2024, then slumped by 1531.78% to -$4.6 million in 2025.
- The last three Other financing activities figures came in at -$4.6 million (Q4 2025), $4.7 million (Q2 2025), and $321000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.60 Mn |
| Dec 31, 2025 | -4.60 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Dec 31, 2024 | 321,000.00 |
| Dec 31, 2024 | 321,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Dec 31, 2023 | 22.38 Mn |
| Dec 31, 2023 | 22.38 Mn |
| Sep 30, 2023 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |